Sonia Moretti

List of Publications by Year
in descending order

54	1,622	304743 22	289244 40
papers	citations	h-index	g-index

54	54	54	1467
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.. EBioMedicine, 2021, 66, 103306.	6.1	11
2	New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. Archives of Virology, 2021, 166, 2955-2974.	2.1	6
3	Advances in SIV/SHIV Non-Human Primate Models of NeuroAIDS. Pathogens, 2021, 10, 1018.	2.8	15
4	HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. International Journal of Molecular Sciences, 2021, 22, 317.	4.1	12
5	Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy. Pathogens, 2021, 10, 1488.	2.8	5
6	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Review of Vaccines, 2020, 19, 71-84.	4.4	12
7	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. Vaccines, 2019, 7, 99.	4.4	14
8	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. Frontiers in Immunology, 2019, 10, 233.	4.8	23
9	â€œcART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studiesâ€• Expert Review of Vaccines, 2017, 17, 1-12.	4.4	4
10	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology, 2016, 13, 34.	2.0	33
11	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology, 2015, 12, 33.	2.0	55
12	Biocompatible Anionic Polymeric Microspheres as Priming Delivery System for Effetive HIV/AIDS Tat-Based Vaccines. PLoS ONE, 2014, 9, e111360.	2.5	4
13	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. PLoS ONE, 2012, 7, e48781.	2.5	56
14	A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Vaccine, 2011, 29, 2918-2932.	3.8	20
15	Containment of Infection in Tat Vaccinated Monkeys After Rechallenge with a Higher Dose of SHIV89.6P_{cy243}. Viral Immunology, 2009, 22, 117-124.	1.3	18
16	HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection. Journal of Immunology, 2009, 182, 2888-2897.	0.8	65
17	Lymphocyte Apoptosis, Caspase Activation and Inflammatory Response in Septic Shock. Infection, 2008, 36, 485-487.	4.7	21
18	Viral outcome of simianâ€“human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Archives of Virology, 2008, 153, 463-472.	2.1	18

#	Article	IF	Citations
19	Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opinion on Emerging Drugs, 2007, 12, 23-48.	2.4	31
20	5-S-Cysteinyl-dopamine effect on the human dopaminergic neuroblastoma cell line SH-SY5Y. Neurochemistry International, 2006, 49, 262-269.	3.8	21
21	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine, 2004, 22, 3258-3269.	3.8	70
22	Oxidative stress and mitochondrial glutathione in human lymphocytes exposed to clinically relevant anesthetic drug concentrations. Journal of Clinical Anesthesia, 2004, 16, 189-194.	1.6	21
23	Apoptogenic Effect of Fentanyl on Freshly Isolated Peripheral Blood Lymphocytes. Journal of Trauma, 2004, 57, 75-81.	2.3	23
24	Pancuronium bromide, a non-depolarizing muscle relaxant which promotes apoptosis of blood lymphocytes in vitro. Acta Anaesthesiologica Scandinavica, 2003, 47, 1138-1144.	1.6	6
25	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. DNA and Cell Biology, 2002, 21, 599-610.	1.9	35
26	Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses. Journal of Immunology, 2002, 168, 197-206.	0.8	158
27	Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. Biochemical Pharmacology, 2002, 63, 1305-1314.	4.4	32
28	L-Carnitine Reduces Lymphocyte Apoptosis and Oxidant Stress in HIV-1-Infected Subjects Treated with Zidovudine and Didanosine. Antioxidants and Redox Signaling, 2002, 4, 391-403.	5.4	65
29	Mitochondrial Perturbations and Oxidant Stress in Lymphocytes From Patients Undergoing Surgery and General Anesthesia. Archives of Surgery, 2001, 136, 1190.	2.2	34
30	Interleukin-10 and Apoptotic Death of Circulating Lymphocytes in Surgical/Anesthesia Trauma. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 51, 92-97.	2.4	25
31	Circulating neutrophils exhibit enhanced apoptosis associated with mitochondrial dysfunctions after surgery under general anaesthesia. Acta Anaesthesiologica Scandinavica, 2001, 45, 87-94.	1.6	22
32	Apoptosis and apoptosis-associated perturbations of peripheral blood lymphocytes during HIV infection: comparison between AIDS patients and asymptomatic long-term non-progressors. Clinical and Experimental Immunology, 2000, 122, 364-373.	2.6	41
33	Apoptosis and Surgical Trauma. Archives of Surgery, 2000, 135, 1141.	2.2	66
34	Symptomatic Crystalluria Associated with Indinavir. Annals of Pharmacotherapy, 2000, 34, 1414-1418.	1.9	17
35	Combined Antiviral Therapy Reduces Hiv-1 Plasma Load and Improves CD4 Counts But Does Not Intere with Ongoing Lymphocyte Apoptosis. Immunopharmacology and Immunotoxicology, 1999, 21, 645-665.	2.4	3
36	Acetyl-l-carnitine Administration Increases Insulin-like Growth Factor 1 Levels in Asymptomatic HIV-1-Infected Subjects: Correlation with Its Suppressive Effect on Lymphocyte Apoptosis and Ceramide Generation. Clinical Immunology, 1999, 92, 103-110.	3.2	61

#	Article	IF	Citations
37	Reduction of Glutamate Levels in HIV-Infected Subjects Treated with Acetylcarnitine. Journal of Neuro-AIDS, 1999, 2, 65-73.	0.2	4
38	Effect of L-Carnitine on Human Immunodeficiency Virus-1 Infection-Associated Apoptosis: A Pilot Study. Blood, 1998, 91, 3817-3824.	1.4	63
39	Effect of L-Carnitine on Human Immunodeficiency Virus-1 Infection-Associated Apoptosis: A Pilot Study. Blood, 1998, 91, 3817-3824.	1.4	0
40	Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. Aids, 1997, 11, 185-190.	2.2	114
41	L-Carnitine, a Modulator of Immunometabolic Homeostasis in Subjects Infected with the Human Immunodeficiency Virus. , 1997, , 215-231.		2
42	Cell-associated ceramide in HIV-1 -infected subjects. Aids, 1996, 10, 675.	2.2	20
43	EFFECT OF l-CARNITINE TREATMENT IN VIVO ON APOPTOSIS AND CERAMIDE GENERATION IN PERIPHERAL BLOOD LYMPHOCYTES FROM AIDS PATIENTS: CORRELATION WITH IN VITRO RESULTS. Biochemical Society Transactions, 1996, 24, 618S-618S.	3.4	1
44	Ceramide, AIDS and long-term survivors. Trends in Immunology, 1996, 17, 48.	7.5	19
45	Defective production of interferon-Î³ and tumour necrosis factor-Î± by AIDS mononuclear cells after in vitro exposure to Rhodococcus equi. Mediators of Inflammation, 1995, 4, 306-309.	3.0	8
46	Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS. Aids, 1994, 8, 655-660.	2.2	81
47	High Dose L-Carnitine Improves Immunologic and Metabolic Parameters in Aids Patients. Immunopharmacology and Immunotoxicology, 1993, 15, 1-12.	2.4	69
48	In Vivo and in Vitro Efficacy of Fusidic Acid in HIV Infection. Annals of the New York Academy of Sciences, 1993, 685, 341-343.	3.8	9
49	L-carnitine: a partner between immune response and lipid metabolism ?. Mediators of Inflammation, 1993, 2, S29-S32.	3.0	4
50	Effect ofBifidobacterium bifidumandLactobacillus acidophiluson gut mucosa and peripheral blood B lymphocytes. Immunopharmacology and Immunotoxicology, 1992, 14, 331-340.	2.4	81
51	AIDS Patients with Bacterial Lower Respiratory Tract Infections: Treatment with Ofloxacin versus Sulbactam-Ampicillin. Journal of Chemotherapy, 1992, 4, 376-380.	1.5	0
52	Open Randomized Controlled Parallel Study of Ofloxacin versus Trimethoprim-Sulfamethoxazole Treatment of Lower Respiratory Tract and Urinary Infections. Chemotherapy, 1991, 37, 39-48.	1.6	3
53	Inosine pranobex in the treatment of HIV infection: A review. International Journal of Immunopharmacology, 1991, 13, 19-27.	1.1	21
54	Synthetic immunomodulators. Cytotechnology, 1991, 5, 11-14.	1.6	0